Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer takes a middle-of-the-road approach to breaking out non-core businesses, announcing plans to explore alternatives for Animal Health and Nutrition.
You may also be interested in...
Stockwatch: Biosimilars And Dividends Connect Earnings At Pfizer And Roche
With Brexit and coronavirus depressing markets over the week, earnings season for life science companies shifted into a higher gear with a number of big companies reporting. In time, the effects of Brexit and 2019-nCoV are likely to subside, but the double-edge sword of biosimilar commercialization continues to rise from the full-year financial reports of Pfizer and Roche.
At Pfizer, A Split A Decade In The Making
Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.
No Near-Term Separations For Pfizer, But Business Model Will “Evolve”
Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.